Medications for dry eye syndrome: a drug-therapy review.
Early interventions were palliative, attempting to replace water lost from the tear film. Today, therapy is directed at the underlying inflammation, a recognized component of dry eye syndrome, and at the resulting progressive changes to the ocular surface. This approach offers promise of lasting relief to patients with moderate to severe symptoms.
Perry
Henry D
HD
Weill School of Medicine, Cornell University, USA.
Donnenfeld
Eric D
ED
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D016568:Drugs, Generic; D006801:Humans; D007249:Inflammation; D007638:Keratoconjunctivitis Sicca / Q000188:drug therapy* / Q000473:pathology; D009883:Ophthalmic Solutions / Q000627:therapeutic use; D013666:Tears / Q000378:metabolism; D014481:United States
D000305:Adrenal Cortex Hormones; D016568:Drugs, Generic; D009883:Ophthalmic Solutions; D016572:Cyclosporine